Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIM-3 vemurafenib versus dacarbazine in previously untreated BRAF V600E-mutant advanced melanoma
NL-OMON39219Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of vemurafenib, sponsored by Roche. Planned start Dec 2009; status: not yet recruiting.
02
Drugs
vemurafenib
Beyond the preview
Go deeper on NL-OMON39219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39219.